News
-
-
COMMUNIQUÉ DE PRESSE
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
BioVersys receives US FDA green light for BV100 HABP/VABP Phase 3 pivotal trial start to address CRABC infections in hospital-acquired bacterial pneumonia. A significant step in developing novel antibacterial products for MDR bacteria -
-
-
COMMUNIQUÉ DE PRESSE
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
BioVersys announces the first patient dosed in a Phase 2b clinical trial of AlpE for pulmonary tuberculosis, collaborating with GSK under UNITE4TB project. Results expected by end of 2027 -
-
-
COMMUNIQUÉ DE PRESSE
BioVersys to Report its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call
BioVersys AG to report Full Year 2025 financial results, provide business update, and host conference call on March 18, 2026. Focus on antibacterial products for MDR bacteria -
-
